Johnson & Johnson (JNJ) Announces Updated Results From the Phase 3 CARTITUDE-4 Study

Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in. Johnson & Johnson (NYSE:JNJ) announced on December 6 the updated results from the Phase 3 CARTITUDE-4 study that supported durable treatment-free remissions as early as second line treatment with CARVYKTI, reporting that the disease did not progress and no further treatment was required at 30 months in 80% of as-treated patients with relapsed or refractory multiple myeloma (RRMM) and standard-risk cytogenetics treated with CARVYKTI as early as first relapse.

Management reported that additional translational analyses shows that the patients who received CARVYKTI in earlier lines exhibited improved immune fitness, which draws a correlation with longer progression-free survival (PFS). Luciano J. Costa, M.D., Ph.D., Professor of Medicine at the University of Alabama and principal investigator of the CARTITUDE-4 study, stated that the data hints that a single infusion of CARVYKTI for standard-risk patients may offer additional advantages as early as the second line of therapy, and that deeper and more durable responses can be acheived by treating patients with multiple myeloma after first relapse. This, according to Luciano, can push the treatment paradigm closer to a potential long-term remission, and ultimately, cure.

Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.